| Lizenz: Creative Commons Namensnennung-NichtKommerziell 4.0 International PDF - Veröffentlichte Version (876kB) |
- URN zum Zitieren dieses Dokuments:
- urn:nbn:de:bvb:355-epub-442745
- DOI zum Zitieren dieses Dokuments:
- 10.5283/epub.44274
Zusammenfassung
Aims Recent clinical trials have proven gliflozins to be cardioprotective in diabetic and non-diabetic patients. However, the underlying mechanisms are incompletely understood. A potential inhibition of cardiac Na+/H(+)exchanger 1 (NHE1) has been suggested in animal models. We investigated the effect of empagliflozin on NHE1 activity in human atrial cardiomyocytes. Methods and results Expression ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags
Downloadstatistik